| Patient | Frederick Cook |
|---|---|
| Date of birth | 1865-06-10 |
| Identifiers | MRN HR-EX006-SYN-TD; SSN (made up) 000-06-4471 |
| Document date | 1930-08-18 |
| Author | Harriet Okafor-Brandt, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review of blood pressure, electrolytes and kidney function four weeks after starting hydrochlorothiazide and amlodipine. [S]
Mr. Cook returns four weeks after starting hydrochlorothiazide 25 mg, amlodipine 5 mg, atorvastatin 40 mg and aspirin 81 mg. He has missed no doses. He urinates more in the mornings but has no dizziness on standing, cramps, ankle swelling, muscle aches, indigestion or bruising. His home readings over the past week average 136/82. He has had no stroke symptoms. He had the echocardiogram this morning. He signed a weekly lease for his room and is waiting for his benefits decision. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 136/82 over the past week |
| Medicine effects | More morning urination; no dizziness, cramps, swelling, muscle aches or bleeding |
| Stroke symptoms | None |
| Social | Room settled; benefits decision pending |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain or ankle swelling |
| Neurological | Negative | No weakness, numbness, speech trouble, or dizziness on standing |
| Musculoskeletal | Negative | No muscle aches or cramps |
| Gastrointestinal | Negative | No indigestion or black stools |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg tablet, one tablet by mouth each morning | once daily in the morning | Oral route | 1930-07-21 to 1930-09-29 | completed | S |
| Amlodipine 5 mg tablet, one tablet by mouth daily | once daily | Oral route | 1930-07-21 | active | S |
| Atorvastatin 40 mg tablet, one tablet by mouth daily | once daily | Oral route | 1930-07-21 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | once daily | Oral route | 1930-07-21 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1930-08-18 | Body height | 175 | cm | S |
| 1930-08-18 | Body weight | 75.4 | kg | S |
| 1930-08-18 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 1930-08-18 | Systolic blood pressure | 138 | mm[Hg] | S |
| 1930-08-18 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 1930-08-18 | Heart rate | 70 | /min | S |
| 1930-08-18 | Respiratory rate | 14 | /min | S |
| 1930-08-18 | Body temperature | 36.6 | Cel | S |
| 1930-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1930-08-18 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 136-145 mmol/L | Normal | S |
| 1930-08-18 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1930-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1930-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1925)/1.73 sq M | 82 | mL/min/{1.73_m2} | 60 or more | Normal | S |
Vital signs recorded on 1930-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 138/84, pulse 70, weight 75.4 kg; no drop on standing |
| Neck | Soft right carotid bruit, unchanged |
| Cardiovascular | Regular rhythm; no ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at the first visit, 166/94 mmHg (average of two seated readings), without a previous diagnosis of hypertension; no symptoms; out-of-office confirmation with a week of home readings requested | resolved | confirmed | R03.0 | S — Synthetic presenting finding at re-entry; superseded by the diagnosis at the second visit. |
| Essential hypertension, stage 2, confirmed by home readings averaging 154/90 mmHg; no left ventricular hypertrophy on ECG; urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis made at the second visit. |
| Right carotid bruit heard at the first visit in a man with no symptoms of stroke or transient ischemic attack; carotid duplex ultrasound and vascular neurology consultation requested | resolved | confirmed | R09.89 | S — Synthetic examination finding; superseded by the duplex result at the second visit. |
| Asymptomatic atherosclerotic stenosis of the right internal carotid artery, 50 to 69 percent by duplex ultrasound, with less than 50 percent plaque on the left; no stroke or transient ischemic attack; managed with best medical therapy (blood pressure control, a statin and low-dose aspirin) and yearly duplex surveillance | active | confirmed | I65.21 | S — Synthetic modern diagnosis made at the vascular neurology consultation; not a claim about his real arteries. |
| Recent release from about six years of incarceration: re-entering community life on parole at 65, establishing primary care with no medical records yet received, a rented room, no earned income, and a public reputation he feels as a burden | active | confirmed | Z65.2 | S — Synthetic modern social problem anchored to his documented imprisonment and parole. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure, seated, average of two readings | Every visit | Completed today | 138/84 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and after each treatment change | Completed today | Average 136/82 over the past week |
| Laboratory | Sodium, potassium, creatinine and eGFR | Baseline; early after starting a diuretic or an ARB; then every 6 months | Completed today | Sodium 136, potassium 3.6 mmol/L, creatinine 1.02 mg/dL, eGFR 82, four weeks after starting hydrochlorothiazide |
| Laboratory | Lipid panel | Baseline; 4 to 12 weeks after starting a statin; then every 3 to 12 months | Due | Due at the next visit, ten weeks after starting atorvastatin |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Completed today | No left ventricular hypertrophy; ejection fraction about 60 percent; mild aortic sclerosis |
| Medication safety | Diuretic effects: orthostatic symptoms, cramps, sodium and potassium | Early after starting, then every visit | Completed today | No orthostatic drop; sodium and potassium low-normal |
| Medication safety | Antiplatelet adherence and bleeding | Every visit | Completed today | Taking aspirin daily; no bleeding or indigestion |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | No muscle symptoms |
| Self-management | Stroke warning signs (BE FAST) and calling 911 | Every visit | Completed today | No symptoms; knows the signs |
| Self-management | Re-entry social needs: housing, income, benefits, records | Every visit until settled | Completed today | Weekly lease signed; benefits pending |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (Jones DW, et al. Hypertension 2025;82:e212-e316) (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and stroke/TIA monographs (2026); 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association (Bushnell C, et al. Stroke 2024;55:e344-e424) (2024); 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy SM, et al. Circulation 2019;139:e1082-e1143) (2018)
Follow-up: Twelve-week review in six weeks, with electrolytes, a lipid panel and ALT. Next scheduled visit 1930-09-29: twelve-week review: blood pressure and lipids after a gout flare on hydrochlorothiazide; switch to losartan. [S]